open access (pdf)
Monday, July 11, 2016
Robot-assisted nephroureterectomy: current perspectives
open access
Conclusion
RALNU has emerged as a novel minimally invasive
alternative to laparoscopic and open NU and has demonstrated promising
early results. With experience and progress in the technology of the da
Vinci robotic system, the need for intraoperative redocking or
repositioning of the patients is reduced. However, RALNU is still
lacking long-term reports on perioperative and oncological outcomes,
even though intermediate outcomes and analyses have shown oncological
equivalency when compared to other approaches. Cost efficacy studies and
quality of life analysis are required to justify the higher
non-negligible costs associated with RALNU.
Special Edition: Future Oncology: Oncofertility
Vol. 12
Special Focus Issue: Oncofertility – Foreword
 The challenge of fertility preservation in cancer patients: a special focus issue from Future Oncology |
Editorial
| Endocrine prevention of chemotherapy-induced ovarian failure |
Fertility preservation in cancer patients with a poor prognosis: the controversy of posthumous reproduction
Janella Hudson , Susan T Vadaparampil , Christina Tamargo , Gwendolyn P Quinn
Citation | Full Text | PDF (1617 KB) | PDF Plus (1625 KB)
| Reprints
&
Permissions |
The importance of actively involving partners in oncofertility discussions
Hoda Badr
Citation | Full Text | PDF (1688 KB) | PDF Plus (1702 KB)
| Reprints
&
Permissions |
Oncofertility in gynecologic oncology: an oxymoron?
Dana Marie Roque , Alessandro D Santin
Citation | Full Text | PDF (1991 KB) | PDF Plus (2008 KB)
| Reprints
&
Permissions |
Commentary
Combating radiation therapy-induced damage to the ovarian environment
Francesca E Duncan , Bruce F Kimler , Shawn M Briley
Citation | Full Text | PDF (2393 KB) | PDF Plus (2415 KB)
| Reprints
&
Permissions |
State-of-the art advances in fertility preservation for the male cancer patient
Dana Livne-Segev , Ellen C Forbes , Kirk C Lo
Citation | Full Text | PDF (1656 KB) | PDF Plus (1677 KB)
| Reprints
&
Permissions |
Fertility preservation option in young women with ovarian cancer
So-Youn Kim , Jung Ryeol Lee
Citation | Full Text | PDF (2010 KB) | PDF Plus (2031 KB)
| Reprints
&
Permissions |
Research Article
Doxorubicin and cisplatin induce apoptosis in ovarian stromal cells obtained from cryopreserved human ovarian tissue
Raffaella Fabbri , Maria Macciocca , Rossella Vicenti , Roberto Paradisi , Francesca Gioia Klinger , Gianandrea Pasquinelli , Enzo Spisni , Renato Seracchioli , Alessio Papi
Summary | Full Text | PDF (3543 KB) | PDF Plus (3599 KB) | Supplementary Material
| Reprints
&
Permissions |
History of ABVD alters the number of oocytes vitrified after in vitro maturation in fertility preservation candidates
Charlotte Sonigo , Alice Seroka , Isabelle Cédrin-Durnerin , Nathalie Sermondade , Christophe Sifer , Michael Grynberg
Summary | Full Text | PDF (1715 KB) | PDF Plus (1751 KB)
| Reprints
&
Permissions |
Review
The effects of cancer therapy on women's fertility: what do we know now?
Barbara Lawrenz , Nalini Mahajan , Human Mousavi Fatemi
Summary | Full Text | PDF (1730 KB) | PDF Plus (1769 KB)
| Reprints
&
Permissions |
Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art
Julie Bénard , Solène Duros , Hady El Hachem , Charlotte Sonigo , Christophe Sifer , Michaël Grynberg
Summary | Full Text | PDF (4977 KB) | PDF Plus (5054 KB)
| Reprints
&
Permissions |
ESMO Patient Program Sept 8-9, 2016
Patient Program
The fourth patient seminar will take place in Antalya, Turkey during the ESGO 2016 State of the Art conference.
For more information view the detailed programme of the patient seminar.
Thursday, June 30, 2016
Sensitivity of BRCA1/2 testing in high-risk breast ovarian male breast cancer families...
Abstract
Sensitivity of BRCA1|[sol]|2 testing in high-risk breast|[sol]|ovarian|[sol]|male breast cancer families: little contribution of comprehensive RNA|[sol]|NGS panel testing
The
sensitivity of testing BRCA1 and BRCA2 remains unresolved as the
frequency of deep intronic splicing variants has not been defined in
high-risk familial breast/ovarian cancer
families. This variant category is reported at significant frequency in
other tumour predisposition genes, including NF1 and MSH2. We carried
out comprehensive whole gene RNA analysis on 45 high-risk breast/ovary
and male breast cancer families with no identified pathogenic variant
on exonic sequencing and copy number analysis of BRCA1/2. In addition, we undertook variant screening of a 10-gene high/moderate risk breast/ovarian cancer panel by next-generation sequencing. DNA testing identified the causative variant in 50/56 (89%) breast/ovarian/male
breast cancer families with Manchester scores of ≥50 with two variants
being confirmed to affect splicing on RNA analysis. RNA sequencing of
BRCA1/BRCA2 on 45 individuals from high-risk
families identified no deep intronic variants and did not suggest loss
of RNA expression as a cause of lost sensitivity. Panel testing in 42
samples identified a known RAD51D variant, a high-risk ATM variant in
another breast ovary family and a truncating CHEK2 mutation. Current
exonic sequencing and copy number analysis variant detection methods of
BRCA1/2 have high sensitivity in high-risk breast/ovarian cancer families. Sequence analysis of RNA does not identify any variants undetected by current analysis of BRCA1/2.
However, RNA analysis clarified the pathogenicity of variants of
unknown significance detected by current methods. The low diagnostic
uplift achieved through sequence analysis of the other known breast/ovarian cancer susceptibility genes indicates that further high-risk genes remain to be identified.
Leukaemia drug shows potential for rare type of ovarian cancer (clear cell/dasatinib/ARIDIA)
press release
June 30, 2016
The mutation is found in around half of patients diagnosed with ovarian
clear cell carcinoma. References
*Miller et al., Synthetic Lethal Targeting of ARID1A mutant ovarian clear cell tumours with dasatinib. Molecular Cancer Therapeutics, 2016don’t yet know exactly how it is linked to cancer.Ovarian cancer study (serous) uncovers new biology: Proteogenomics provides new inroads to diagnosis, treatment
science news
June 29, 2016
Source: Johns Hopkins Medicine
- Summary:
- In what is believed to be the largest study of its kind, scientists led a study that examined the proteomes of 169 ovarian cancer patients to identify critical proteins expressed by their tumors.
"But just like anything in medicine, clinical validation will be a long and rigorous process."
Johns Hopkins media release June 29, 2016
....Using protein measurement and identification techniques, such as mass spectrometry, the teams identified 9,600 proteins in all the tumors and pursued study on 3,586 proteins common to all 169 tumor samples.....chromosomes 2, 7, 20 and 22...
New ovarian cancer drugs raise hope, but not for all (geography/Tesaro/niraparib)
medical news
Promising new therapies are springing up to treat ovarian cancer, long one of the most deadly and hard to treat malignancies.
The latest: An experimental drug from Tesaro, a small biotech company based in Waltham, Mass. The company on Wednesday released exciting clinical trial data for an experimental drug that’s meant to stop cancer cells from repairing themselves after they’ve been hit by chemotherapy.
Patients with recurring ovarian cancer who took
the drug got as much as an additional 15 months with no growth in their
tumors, as compared to a control group, the company said. The news sent stock prices soaring.
The catch? Even with new drugs, ovarian cancer mortality is likely to remain high.
One reason: Geography.
“It’ll get worse,” said Dr. Leslie Randall, an associate professor of gynecologic oncology at the University of California, Irvine. “As we come out with more novel treatments that are more complex to deliver, that disparity will only get worse.”
Subscribe to:
Posts
(
Atom
)
